Alyeska Investment Group
UROV

Alyeska Investment Group’s Urovant Sciences Ltd. UROV Stock Holding History

Alyeska Investment Group’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-620,889
Closed -$5.8M – 678
2020
Q3 		$5.8M Hold
620,889
– – 0.09% 239
2020
Q2 		$6.11M Buy
620,889
+137,721
+29% +$1.32M 0.09% 246
2020
Q1 		$4.46M Buy
483,168
+305,437
+172% +$3.67M 0.09% 201
2019
Q4 		$2.76M Buy
+177,731
New +$1.93M 0.04% 271

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
OCM
Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Alyeska Investment Group's UROV Position: Q4 2020 in Review

Alyeska Investment Group sold out of Urovant Sciences Ltd. (UROV) in Q4 2020, closing a stake of 620,889 shares — an estimated $5.8M sold.

Alyeska Investment Group first reported a position in UROV in Q4 2019 and held it in 4 quarters. The position peaked at $6.11M in Q2 2020. 41 funds tracked by Wall St. Rank hold UROV as of Q4 2020.

  • Alyeska Investment Group reported no remaining Urovant Sciences Ltd. position as of Q4 2020 after selling out during the quarter.
  • Alyeska Investment Group sold 620,889 Urovant Sciences Ltd. shares in Q4 2020, an estimated $5.8M.
  • Alyeska Investment Group first reported a position in Urovant Sciences Ltd. in Q4 2019 and held it in 4 quarters.
  • Alyeska Investment Group's Urovant Sciences Ltd. position peaked at $6.11M in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2020.

Based on Alyeska Investment Group's 13F filing for Q4 2020, filed 16 Feb 2021.